George Rodrigues1, Andrew Warner2, Jaap Zindler3, Ben Slotman3, Frank Lagerwaard3. 1. Department of Radiation Oncology, London Regional Cancer Program, Canada; Department of Epidemiology and Biostatistics, University of Western Ontario, London, Canada. Electronic address: george.rodrigues@lhsc.on.ca. 2. Department of Radiation Oncology, London Regional Cancer Program, Canada. 3. Department of Radiation Oncology, VU University Medical Center, Amsterdam, The Netherlands.
Abstract
PURPOSE: This investigation defined patient populations at high-, intermediate-, and low-risk of regional failure (RF) after stereotactic radiosurgery (SRS) lesion treatment using clinical nomograms and recursive partitioning analysis (RPA). METHODS AND MATERIALS: We created a retrospective database compiling 361 oligometastatic brain metastases patients treated with single-modality Linac-based SRS. Logistic analysis was performed to identify factors to be included in a RPA to predict for cumulative RF at 1-year. A 1-year cumulative RF clinical nomogram was constructed and validated (c-index statistic). RESULTS: Age, number of brain metastases, World Health Organization (WHO) performance status (PS), and maximum gross tumor volume (GTV) size were found to be statistically significant predictors of the primary outcome. RPA classifications were defined as follows: low-risk (<25% 1-year RF): solitary lesion AND age >55Y; intermediate-risk (25-40% 1-year RF): age ⩽55Y AND solitary lesion OR WHO⩾1 AND 2-3 lesions; and high-risk (>40% 1-year RF): WHO PS=0 AND 2-3 lesions. These classifications were highly statistically significant (p<0.01) for RF. A clinical nomogram (containing patient age, lesion number, largest GTV volume, and WHO PS) for the prediction of 1-year cumulative RF was created (c-index 0.69). CONCLUSION: A risk-adapted treatment approach can be applied for BM radiosurgery either using RPA categories and/or nomogram-based risk estimates.
PURPOSE: This investigation defined patient populations at high-, intermediate-, and low-risk of regional failure (RF) after stereotactic radiosurgery (SRS) lesion treatment using clinical nomograms and recursive partitioning analysis (RPA). METHODS AND MATERIALS: We created a retrospective database compiling 361 oligometastatic brain metastasespatients treated with single-modality Linac-based SRS. Logistic analysis was performed to identify factors to be included in a RPA to predict for cumulative RF at 1-year. A 1-year cumulative RF clinical nomogram was constructed and validated (c-index statistic). RESULTS: Age, number of brain metastases, World Health Organization (WHO) performance status (PS), and maximum gross tumor volume (GTV) size were found to be statistically significant predictors of the primary outcome. RPA classifications were defined as follows: low-risk (<25% 1-year RF): solitary lesion AND age >55Y; intermediate-risk (25-40% 1-year RF): age ⩽55Y AND solitary lesion OR WHO⩾1 AND 2-3 lesions; and high-risk (>40% 1-year RF): WHO PS=0 AND 2-3 lesions. These classifications were highly statistically significant (p<0.01) for RF. A clinical nomogram (containing patient age, lesion number, largest GTV volume, and WHO PS) for the prediction of 1-year cumulative RF was created (c-index 0.69). CONCLUSION: A risk-adapted treatment approach can be applied for BM radiosurgery either using RPA categories and/or nomogram-based risk estimates.
Authors: Gregory W Hruby; Luke V Rasmussen; David Hanauer; Vimla L Patel; James J Cimino; Chunhua Weng Journal: Int J Med Inform Date: 2016-06-16 Impact factor: 4.046
Authors: Diandra N Ayala-Peacock; Albert Attia; Steve E Braunstein; Manmeet S Ahluwalia; Jaroslaw Hepel; Caroline Chung; Joseph Contessa; Emory McTyre; Ann M Peiffer; John T Lucas; Scott Isom; Nicholas M Pajewski; Rupesh Kotecha; Mark J Stavas; Brandi R Page; Lawrence Kleinberg; Colette Shen; Robert B Taylor; Nasarachi E Onyeuku; Andrew T Hyde; Daniel Gorovets; Samuel T Chao; Christopher Corso; Jimmy Ruiz; Kounosuke Watabe; Stephen B Tatter; Gelareh Zadeh; Veronica L S Chiang; John B Fiveash; Michael D Chan Journal: J Neurooncol Date: 2017-08-21 Impact factor: 4.130
Authors: Yufei Liu; Brian M Alexander; Yu-Hui Chen; Margaret C Horvath; Ayal A Aizer; Elizabeth B Claus; Ian F Dunn; Alexandra J Golby; Mark D Johnson; Scott Friesen; Edward G Mannarino; Matthew Wagar; Fred L Hacker; Nils D Arvold Journal: J Neurooncol Date: 2015-06-25 Impact factor: 4.130
Authors: Michael C LeCompte; Emory McTyre; Adrianna Henson; Michael Farris; Catherine Okoukoni; Christina K Cramer; Pierre Triozzi; Jimmy Ruiz; Kounosuke Watabe; Hui-Wen Lo; Michael T Munley; Adrian W Laxton; Stephen B Tatter; Xiaobo Zhou; Michael Chan Journal: Cureus Date: 2017-12-11
Authors: Roshan S Prabhu; Robert H Press; Danielle M Boselli; Katherine R Miller; Scott P Lankford; Robert J McCammon; Benjamin J Moeller; John H Heinzerling; Carolina E Fasola; Kirtesh R Patel; Anthony L Asher; Ashley L Sumrall; Walter J Curran; Hui-Kuo G Shu; Stuart H Burri Journal: J Neurooncol Date: 2017-12-07 Impact factor: 4.130
Authors: Robert H Press; Roshan S Prabhu; Dana C Nickleach; Yuan Liu; Hui-Kuo G Shu; Shravan Kandula; Kirtesh R Patel; Walter J Curran; Ian Crocker Journal: Cancer Date: 2015-08-04 Impact factor: 6.860
Authors: Brahma D Natarajan; Christel N Rushing; Michael A Cummings; Jessica Ms Jutzy; Kingshuk R Choudhury; Michael J Moravan; Peter E Fecci; Justus Adamson; Steven J Chmura; Michael T Milano; John P Kirkpatrick; Joseph K Salama Journal: J Radiosurg SBRT Date: 2019
Authors: Ali Rae; Daniel Gorovets; Paul Rava; Daniel Ebner; Deus Cielo; Timothy J Kinsella; Thomas A DiPetrillo; Jaroslaw T Hepel Journal: Adv Radiat Oncol Date: 2016-08-24